Amphastar Subsidiary Receives FDA Warning Letter
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 7 hours ago
0mins
Source: seekingalpha
- FDA Warning Letter: Amphastar Pharmaceuticals' subsidiary, International Medication Systems, received a warning letter from the FDA on July 2 due to manufacturing violations found during a December inspection at its South El Monte, California facility, which could negatively impact the company's reputation and market trust.
- Remediation Plan: The company has stated in a regulatory filing that it has implemented a remediation plan to address the FDA's concerns; although production and supply remain unrestricted, the company is still assessing the potential business impact of the warning letter, which may lead to increased compliance costs in the future.
- Inspection Findings: The FDA's warning letter included a Form 483 detailing issues related to handling and investigation procedures, environmental monitoring, and manufacturing equipment, which could affect product quality and safety, posing a threat to the company's future sales and market share.
- Financial Performance: Amphastar's recent earnings report indicated a non-GAAP EPS of $0.42, missing expectations by $0.29, with revenue of $171.2 million falling short by $2.19 million, reflecting pressures on the company regarding compliance and market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMPH
Wall Street analysts forecast AMPH stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 20.080
Low
30.00
Averages
32.00
High
34.00
Current: 20.080
Low
30.00
Averages
32.00
High
34.00
About AMPH
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amphastar Subsidiary Receives FDA Warning Letter
- FDA Warning Letter: Amphastar Pharmaceuticals' subsidiary, International Medication Systems, received a warning letter from the FDA on July 2 due to manufacturing violations found during a December inspection at its South El Monte, California facility, which could negatively impact the company's reputation and market trust.
- Remediation Plan: The company has stated in a regulatory filing that it has implemented a remediation plan to address the FDA's concerns; although production and supply remain unrestricted, the company is still assessing the potential business impact of the warning letter, which may lead to increased compliance costs in the future.
- Inspection Findings: The FDA's warning letter included a Form 483 detailing issues related to handling and investigation procedures, environmental monitoring, and manufacturing equipment, which could affect product quality and safety, posing a threat to the company's future sales and market share.
- Financial Performance: Amphastar's recent earnings report indicated a non-GAAP EPS of $0.42, missing expectations by $0.29, with revenue of $171.2 million falling short by $2.19 million, reflecting pressures on the company regarding compliance and market performance.
See More
Amphastar Pharmaceuticals Q1 2026 Earnings Call Insights
- Return to Revenue Growth: Amphastar Pharmaceuticals reported Q1 revenue of $171.2 million, slightly below analysts' expectations of $173.39 million, yet indicating growth driven by recent product launches, particularly in BAQSIMI and Primatene MIST sales performance.
- Pricing Pressure: BAQSIMI generated $32 million in revenue, a 15% decline year-over-year primarily due to lower average selling prices, reflecting challenges from 340B pharmacy discounts and increased competition, prompting management to implement price increases to mitigate these pressures.
- New Product Launch: The successful launch of AMP-007, the only generic Ipratropium inhalation product, is expected to be the biggest growth driver this year, with management maintaining overall sales guidance for 2026, anticipating mid to high single-digit unit growth.
- Active Capital Allocation: Amphastar accelerated its share repurchase program, buying back $29.5 million worth of shares, representing about 3% of its share count, demonstrating confidence in future growth while actively managing capital allocation to address market challenges.
See More
Amphastar Pharmaceuticals Announces Q1 2026 Earnings Release Schedule
- Earnings Release Schedule: Amphastar Pharmaceuticals will release its Q1 2026 financial results after market close on May 7, 2026, which is expected to provide critical data for assessing the company's performance.
- Conference Call Details: The company will hold a conference call at 2:00 PM Pacific Time to discuss the financial results, with investors encouraged to dial 877-407-0989 (international calls at 201-389-0921) ten minutes prior to the start.
- Webcast Replay: A replay of the conference call will be available on the company's website within 24 hours after the live event, allowing investors who cannot attend in real-time to access the information.
- Company Overview: Amphastar focuses on developing and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, with most finished products distributed through wholesalers and retailers, highlighting its market position in the biopharmaceutical sector.
See More
Amphastar Pharmaceuticals Announces Q1 2026 Earnings Release Schedule
- Earnings Release Schedule: Amphastar Pharmaceuticals will release its Q1 2026 financial results after market close on May 7, 2026, which is expected to provide critical financial data and business trend analysis to help investors assess the company's future growth potential.
- Conference Call Details: The company will hold a conference call at 2:00 p.m. Pacific Time, where investors can participate by dialing 877-407-0989 (U.S.) or 201-389-0921 (international), providing direct financial insights and a Q&A session for stakeholders.
- Webcast Replay: A replay of the earnings call will be available on the company’s website within 24 hours after the live event, ensuring that investors who cannot attend in real-time can access relevant information, thereby enhancing transparency.
- Company Background: Amphastar Pharmaceuticals focuses on developing and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, with most of its products distributed through group purchasing organizations and drug wholesalers, showcasing its extensive market influence.
See More
Amendment to Contract Research Agreement Signed Between Amphastar Pharmaceuticals and Nanjing Hanxin Pharmaceutical Technology on March 3
Company Announcement: AMPHASTAR Pharmaceuticals has entered into an amendment to their research agreement.
Contract Details: The amendment pertains to a contract with Co & Nanjing Hanxin Pharmaceutical Technology.
See More
Flutter Entertainment Reports Disappointing Q4 Results, Shares Plunge
- Disappointing Financial Results: Flutter Entertainment reported Q4 revenue of $4.74 billion, a 25% year-over-year increase, yet it fell short of the market expectation of $4.97 billion, indicating challenges in revenue growth that could impact investor confidence moving forward.
- Earnings Miss: The company posted earnings per share of $1.74, missing the consensus estimate of $1.99, reflecting pressures from rising costs and intensified market competition, which may raise concerns about future profitability among investors.
- Significant Stock Decline: In pre-market trading, Flutter's shares plummeted by 14.8% to $104.84, indicating a strong market reaction to the disappointing earnings report, which could adversely affect the company's short-term market performance.
- Uncertain Future Guidance: Flutter issued weak FY26 revenue guidance in its report, potentially diminishing market confidence in the company's growth prospects and exacerbating stock volatility risks.
See More
Amphastar Subsidiary Receives FDA Warning Letter
- FDA Warning Letter: Amphastar Pharmaceuticals' subsidiary, International Medication Systems, received a warning letter from the FDA on July 2 due to manufacturing violations found during a December inspection at its South El Monte, California facility, which could negatively impact the company's reputation and market trust.
- Remediation Plan: The company has stated in a regulatory filing that it has implemented a remediation plan to address the FDA's concerns; although production and supply remain unrestricted, the company is still assessing the potential business impact of the warning letter, which may lead to increased compliance costs in the future.
- Inspection Findings: The FDA's warning letter included a Form 483 detailing issues related to handling and investigation procedures, environmental monitoring, and manufacturing equipment, which could affect product quality and safety, posing a threat to the company's future sales and market share.
- Financial Performance: Amphastar's recent earnings report indicated a non-GAAP EPS of $0.42, missing expectations by $0.29, with revenue of $171.2 million falling short by $2.19 million, reflecting pressures on the company regarding compliance and market performance.
See More
Amphastar Pharmaceuticals Q1 2026 Earnings Call Insights
- Return to Revenue Growth: Amphastar Pharmaceuticals reported Q1 revenue of $171.2 million, slightly below analysts' expectations of $173.39 million, yet indicating growth driven by recent product launches, particularly in BAQSIMI and Primatene MIST sales performance.
- Pricing Pressure: BAQSIMI generated $32 million in revenue, a 15% decline year-over-year primarily due to lower average selling prices, reflecting challenges from 340B pharmacy discounts and increased competition, prompting management to implement price increases to mitigate these pressures.
- New Product Launch: The successful launch of AMP-007, the only generic Ipratropium inhalation product, is expected to be the biggest growth driver this year, with management maintaining overall sales guidance for 2026, anticipating mid to high single-digit unit growth.
- Active Capital Allocation: Amphastar accelerated its share repurchase program, buying back $29.5 million worth of shares, representing about 3% of its share count, demonstrating confidence in future growth while actively managing capital allocation to address market challenges.
See More
Amphastar Pharmaceuticals Announces Q1 2026 Earnings Release Schedule
- Earnings Release Schedule: Amphastar Pharmaceuticals will release its Q1 2026 financial results after market close on May 7, 2026, which is expected to provide critical data for assessing the company's performance.
- Conference Call Details: The company will hold a conference call at 2:00 PM Pacific Time to discuss the financial results, with investors encouraged to dial 877-407-0989 (international calls at 201-389-0921) ten minutes prior to the start.
- Webcast Replay: A replay of the conference call will be available on the company's website within 24 hours after the live event, allowing investors who cannot attend in real-time to access the information.
- Company Overview: Amphastar focuses on developing and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, with most finished products distributed through wholesalers and retailers, highlighting its market position in the biopharmaceutical sector.
See More
Amphastar Pharmaceuticals Announces Q1 2026 Earnings Release Schedule
- Earnings Release Schedule: Amphastar Pharmaceuticals will release its Q1 2026 financial results after market close on May 7, 2026, which is expected to provide critical financial data and business trend analysis to help investors assess the company's future growth potential.
- Conference Call Details: The company will hold a conference call at 2:00 p.m. Pacific Time, where investors can participate by dialing 877-407-0989 (U.S.) or 201-389-0921 (international), providing direct financial insights and a Q&A session for stakeholders.
- Webcast Replay: A replay of the earnings call will be available on the company’s website within 24 hours after the live event, ensuring that investors who cannot attend in real-time can access relevant information, thereby enhancing transparency.
- Company Background: Amphastar Pharmaceuticals focuses on developing and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, with most of its products distributed through group purchasing organizations and drug wholesalers, showcasing its extensive market influence.
See More
Amendment to Contract Research Agreement Signed Between Amphastar Pharmaceuticals and Nanjing Hanxin Pharmaceutical Technology on March 3
Company Announcement: AMPHASTAR Pharmaceuticals has entered into an amendment to their research agreement.
Contract Details: The amendment pertains to a contract with Co & Nanjing Hanxin Pharmaceutical Technology.
See More
Flutter Entertainment Reports Disappointing Q4 Results, Shares Plunge
- Disappointing Financial Results: Flutter Entertainment reported Q4 revenue of $4.74 billion, a 25% year-over-year increase, yet it fell short of the market expectation of $4.97 billion, indicating challenges in revenue growth that could impact investor confidence moving forward.
- Earnings Miss: The company posted earnings per share of $1.74, missing the consensus estimate of $1.99, reflecting pressures from rising costs and intensified market competition, which may raise concerns about future profitability among investors.
- Significant Stock Decline: In pre-market trading, Flutter's shares plummeted by 14.8% to $104.84, indicating a strong market reaction to the disappointing earnings report, which could adversely affect the company's short-term market performance.
- Uncertain Future Guidance: Flutter issued weak FY26 revenue guidance in its report, potentially diminishing market confidence in the company's growth prospects and exacerbating stock volatility risks.
See More
